{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T21:53:08Z","timestamp":1794606788971,"version":"4.9.1"},"reference-count":52,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Hypertension"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:p>Contemporary anticancer drugs have significantly improved cancer survival at the expense of cardiovascular toxicities, including heart disease, thromboembolic disease, and hypertension. One of the most common side effects of these drugs is hypertension, especially in patients treated with vascular endothelial growth factor inhibitors, as well as tyrosine kinase inhibitors and proteasome inhibitors. Adjunctive therapy, including corticosteroids, calcineurin inhibitors, and nonsteroidal anti-inflammatories, as well as anti-androgen hormone therapy for prostate cancer, may further increase blood pressure in these patients. Cancer therapy\u2013induced hypertension is often dose limiting, increases cardiovascular mortality in cancer survivors, and is usually reversible after interruption or discontinuation of treatment. The exact molecular mechanisms underlying hypertension are unclear, but recent discoveries indicate an important role for reduced nitric oxide generation, oxidative stress, endothelin-1, prostaglandins, endothelial dysfunction, increased sympathetic outflow, and microvascular rarefaction. In addition, genetic polymorphisms in vascular endothelial growth factor receptors are implicated in vascular endothelial growth factor inhibitor\u2013induced hypertension. Diagnosis, management, and follow-up of cancer therapy\u2013induced hypertension follow national hypertension guidelines because evidence-based clinical trials specifically addressing patients who develop hypertension as a result of cancer therapy are currently lacking. Rigorous baseline assessment of patients before therapy is started requires particular emphasis on assessing and treating cardiovascular risk factors. Hypertension management follows guidelines for the general population, although special attention should be given to rebound hypotension after termination of cancer therapy. Management of these complex patients requires collaborative care involving oncologists, cardiologists, hypertension specialists, primary care professionals, and pharmacists to ensure the optimal therapeutic effect from cancer treatment while minimizing competing cardiovascular toxicities.<\/jats:p>","DOI":"10.1161\/hyp.0000000000000224","type":"journal-article","created":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T05:00:37Z","timestamp":1673240437000},"update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":156,"title":["Cancer Therapy\u2013Related Hypertension: A Scientific Statement From the American Heart Association"],"prefix":"10.1161","volume":"80","author":[{"given":"Jordana B.","family":"Cohen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy J.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherry-Ann","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Dent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daan C.H.","family":"van Dorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra M.","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ninian N.","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin Y.","family":"Oudit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhian M.","family":"Touyz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the American Heart Association Council on Hypertension; Council on Arteriosclerosis, Thrombosis and Vascular Biology; and Council on the Kidney in Cardiovascular Disease","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.3205"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30925-9"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01330-1"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab674"},{"key":"e_1_3_1_6_2","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Accessed January 13 2022. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYP.0000000000000065"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy339"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.120.15026"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-45014-4"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.20.2441"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.121.318051"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.115.020406"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2019.11.009"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz766"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0211228"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30578-8"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.06.882"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.09620911"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0025-6196(12)65772-3"},{"key":"e_1_3_1_22_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000840"},{"key":"e_1_3_1_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2005651"},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611310"},{"key":"e_1_3_1_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2017.12.007"},{"key":"e_1_3_1_26_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.044750"},{"key":"e_1_3_1_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-022-01224-0"},{"key":"e_1_3_1_28_2","doi-asserted-by":"publisher","DOI":"10.1177\/2047487318755193"},{"key":"e_1_3_1_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3638"},{"key":"e_1_3_1_30_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.117.10490"},{"key":"e_1_3_1_31_2","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0b013e3283359c79"},{"key":"e_1_3_1_32_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.8890"},{"key":"e_1_3_1_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00247-3"},{"key":"e_1_3_1_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.12.018"},{"key":"e_1_3_1_35_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0042"},{"key":"e_1_3_1_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.12279"},{"key":"e_1_3_1_37_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11050622"},{"key":"e_1_3_1_38_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M602105200"},{"key":"e_1_3_1_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2018.03.022"},{"key":"e_1_3_1_40_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv369"},{"key":"e_1_3_1_41_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00204-012-0821-7"},{"key":"e_1_3_1_42_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0135083"},{"key":"e_1_3_1_43_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf013"},{"key":"e_1_3_1_44_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008944.pub3"},{"key":"e_1_3_1_45_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23882"},{"key":"e_1_3_1_46_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003407.pub5"},{"key":"e_1_3_1_47_2","doi-asserted-by":"publisher","DOI":"10.33549\/physiolres.933332"},{"key":"e_1_3_1_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00290-9"},{"key":"e_1_3_1_49_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109653"},{"key":"e_1_3_1_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jash.2018.03.008"},{"key":"e_1_3_1_51_2","first-page":"1375","article-title":"The renin-angiotensin system blockers as adjunctive therapy for cancer: a meta-analysis of survival outcome.","volume":"21","author":"Li XY","year":"2017","unstructured":"Li, XY, Sun, JF, Hu, SQ. The renin-angiotensin system blockers as adjunctive therapy for cancer: a meta-analysis of survival outcome. Eur Rev Med Pharmacol Sci. 2017;21:1375\u20131383.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"e_1_3_1_52_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw211"},{"key":"e_1_3_1_53_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001056"}],"container-title":["Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/HYP.0000000000000224","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T12:40:37Z","timestamp":1750855237000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/HYP.0000000000000224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.1161\/HYP.0000000000000224"],"URL":"https:\/\/doi.org\/10.1161\/hyp.0000000000000224","relation":{},"ISSN":["0194-911X","1524-4563"],"issn-type":[{"value":"0194-911X","type":"print"},{"value":"1524-4563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"2023-01-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}